Psilocybin-Assisted Therapy
Core Mechanism
Psilocybin disrupts default mode network rigidity; mystical-type experiences occasion lasting shifts in perspective and meaning
Ontology
Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks
Therapeutic Voice
"Whatever comes, let it come. Whatever goes, let it go. Trust the process."
View of the Person
A consciousness constrained by rigid self-referential processing, capable of liberation through ego dissolution
Evidence
FDA: Breakthrough Therapy designation for TRD and MDD
10+ RCTs
Ko et al. (2022)
Strong preliminary evidence. Goodwin et al. (2022) NEJM trial positive. Regulatory pathway ongoing.
Conditions
Epistemology
Blind Spots
Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing
Contraindications
Active psychosis or personal/family history of psychotic disorders, severe cardiovascular conditions, pregnancy, current use of lithium or tramadol, untreated bipolar I disorder, severe personality disorders with poor reality testing
Training
Not yet FDA-approved at federal level. Oregon (Measure 109, operational 2023) and Colorado (Prop 122, implementation in progress) have created state-regulated facilitator pathways with approved training curricula. Multiple pathways exist: (1) state-licensed facilitator (OR/CO) through programs with state-approved curricula, (2) clinical psychedelic therapy training for licensed clinicians (CIIS, IPI, ATMA), (3) research-context training. Some programs serve both states; others are state-specific.
Oregon: OHA-approved training program → state facilitator license. Colorado: DORA Natural Medicine Division → facilitator certification. Clinical: CIIS Certificate in Psychedelic-Assisted Therapies & Research; IPI year-long training. No federal certification pathway.
State facilitator programs: 120–200+ hrs (varies by program), typically including didactic, experiential, practicum, and supervised components. CIIS certificate: multi-semester. IPI: year-long.
Facilitator programs: $5K–15K+ depending on program. CIIS: graduate tuition rates. State licensing fees additional.
Find a Trained Therapist
Philosophical Roots
James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)
Related Modalities
Controversies & Ethical Concerns
Not yet FDA approved. Breakthrough Therapy designation. Standardization of therapy component still developing
Psilocybin-assisted therapy has not received FDA approval. While it holds Breakthrough Therapy designation and multiple Phase 2 trials show promising results for treatment-resistant depression, the therapy component remains unstandardized — there is no consensus on how many sessions, what kind of preparation, what the therapist does during the experience, or how integration should proceed. The FDA's 2024 rejection of MDMA-assisted therapy on methodological grounds raised concerns about whether psychedelic-assisted therapies can meet regulatory standards given the challenges of blinding and expectancy effects.
Researchers note that the evidence base is growing rapidly and that standardization efforts are underway. The Breakthrough Therapy designation reflects the FDA's recognition of preliminary efficacy. Proponents argue that the regulatory framework developed for pharmaceutical drugs may need adaptation for therapies that combine a substance with a psychotherapeutic process.
The rapid commercialization of psychedelic therapy has outpaced safety infrastructure. Reports of sexual abuse by therapists during psychedelic sessions have emerged from both clinical trials and underground settings — the altered state creates extreme vulnerability and power asymmetry. Training standards for psychedelic therapists are not established. The field has attracted significant venture capital investment, creating financial incentives to minimize safety concerns and accelerate access. Oregon's regulated psilocybin program launched without requiring participants to have a clinical diagnosis.
Professional organizations including MAPS and the Psychedelic Medicine Association have developed ethical guidelines. Advocates argue that regulation through frameworks like Oregon's is safer than unregulated underground use. The field is actively developing safety protocols, including requirements for co-therapist teams and video recording of sessions.
Clinical Vignettes
See how Psilocybin-Assisted Therapy formulates these cases:
Test Yourself
Default mode network and psilocybin?
Show answer
DMN active in self-referential thinking. Psilocybin disrupts it, loosening rigid self-narratives.